ne	Form	PTO/SB/08:	Substitute	for form	1440A/DTC
UO.	FOITI	P (U/SB/U6)	Substitute	tor torm	1449A/P1U

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	C	omplete if Known			
	Application Number	09/884,526			
Filing Date		June 19, 2001			
	First Named Inventor	David MEEKER	***************************************		
	Art Unit	1632			
	Examiner Name	Shin-Lin CHEN			
	Attorney Docket Number	07680.0019-00000			

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS						
Examiner	Cite	Document Number	Issue or	ublication Date	Pages, Columns, Lines, Where	
Initials	No.1	Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY		Relevant Passages or Relevant Figures Appear	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>		
		Cristiano et al., <i>Proc. Natl. Acad. Sci. USA</i> 90:11548-11552 (1993). Sustained expression of human factor VIII in mice using a parvovirus-based vector.			
		Brooks, <i>Mol. Genet. Metabol.</i> 68:268-275 (1999). Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models.			

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
David MEEKER et al.	) ) Croup Art Unit: 1622	
Application No.: 09/884,526	) Group Art Unit: 1632	
Filed: June 19, 2001	) ) Examiner: Shin-Lin CHEN	
For: COMBINATION ENZYME REPLACEMENT, GENE THERAPY AND SMALL MOLECULE THERAPY FOR LYSOSOMAL STORAGE DISEASES	) ) Confirmation No.: 2532 ) ) ) )	

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants brings to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law,

U.S.S.N. 09/884,526 Attorney Docket No. 07680.0019-00000

Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Under the provisions of 37 C.F.R. § 1.97(c), please charge the fee of \$180.00 as specified by Section 1.17(p), to deposit account No. 06-0916.

If there are any other fees due in connection with the filing of this Statement, please charge the fees to the same deposit account.

By:

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: August 3, 2006

Konstantin M. Linnik Reg. No. 56,309 Tel. (617) 452-1626